Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide: a randomised crossover pilot study of add-on therapy

TY - JOUR

T1 - Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide

T2 - a randomised crossover pilot study of add-on therapy

AU - Williamson, Peter A

AU - Short, Philip M

AU - Vaidyanathan, Sriram

AU - Lipworth, Brian J

N1 - © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

PY - 2013/1

Y1 - 2013/1

N2 - Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1)

AB - Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1)

U2 - 10.1111/j.1365-2125.2012.04319.x

DO - 10.1111/j.1365-2125.2012.04319.x

M3 - Article

C2 - 22568828

SN - 1365-2125

VL - 75

SP - 93

EP - 102

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -